8-K: Structure Therapeutics' Aleniglipron Shows Strong Obesity Efficacy

Structure Therapeutics Inc. announced positive topline data from its ACCESS clinical program for aleniglipron, a once-daily oral GLP-1 receptor agonist, demonstrating significant weight loss and a favorable safety profile.

Summary

• The Phase 2b ACCESS study demonstrated a placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with the 120 mg dose at 36 weeks.
• The exploratory ACCESS II study showed a placebo-adjusted mean weight loss of up to 15.3% (35.5 lbs) with the 240 mg dose at 36 weeks.
• No adverse event-related treatment discontinuations were observed when starting at the lower 2.5 mg dose in the ACCESS Open Label Extension (OLE) and Body Composition Study.
• Aleniglipron demonstrated clinically meaningful improvements in systolic blood pressure (-6.4 to -7.5 mmHg) and HbA1c (-0.28% to -0.37%).
• The overall adverse event-related treatment discontinuation rate in the Phase 2b ACCESS study was 10.4% across all active arms.
• Aleniglipron exhibited a compelling safety profile with no cases of drug-induced liver injury, persistent liver enzyme elevations, or QTc prolongation across all studies.
• The data from the ACCESS clinical program supports and informs the advancement to Phase 3 clinical development program in mid-2026.

Sentiment

Score: 9

Explanation: The clinical trial results for aleniglipron are overwhelmingly positive, demonstrating significant efficacy, a favorable safety profile, and improved tolerability with dose optimization. The data strongly supports advancement to Phase 3, positioning the company well in a high-demand market.

Positives

• Achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the Phase 2b ACCESS study.
• Demonstrated even greater placebo-adjusted mean weight loss of up to 15.3% (35.5 lbs) with 240 mg dose in the exploratory ACCESS II study at 36 weeks.
• Improved tolerability was observed with a lower 2.5 mg starting dose, leading to no adverse event-related treatment discontinuations in the ACCESS OLE and Body Composition studies.
• No evidence of weight loss plateau was observed through 36-44 weeks in the ACCESS OLE study, suggesting continued efficacy.
• Aleniglipron showed a favorable off-target safety profile, with no drug-induced liver injury, persistent liver enzyme elevations, or QTc prolongation.
• Clinically meaningful improvements were noted in key secondary endpoints, including systolic blood pressure (-6.4 to -7.5 mmHg) and HbA1c (-0.28% to -0.37%).
• A high percentage of participants achieved significant weight loss, with 86% achieving at least 5% weight loss and 70% achieving at least 10% weight loss in the 120 mg dose cohort.
• The comprehensive data package provides a strong foundation for advancing aleniglipron into Phase 3 clinical development.

Negatives

• Gastrointestinal (GI)-related adverse events, such as nausea and vomiting, were the most common AEs, consistent with the GLP-1 receptor agonist class.
• The AE-related treatment discontinuation rate in the Phase 2b ACCESS study ranged from 7.7% to 13.3% (mean 10.4%) across active arms when starting at a 5 mg dose.

Risks

• Topline results are based on preliminary analysis of key efficacy and safety data, which may change following a more comprehensive review and may not accurately reflect complete results.
• The preliminary nature of the results is due to the length of the study and sample size, and results from earlier clinical studies are not necessarily predictive of future results.
• Potential delays in the commencement, enrollment, and completion of planned clinical studies.
• The company's ability to advance aleniglipron and other therapeutic candidates, obtain regulatory approval, and ultimately commercialize them.
• Competitive products or approaches may limit the commercial value of the company's product candidates.
• The timing and results of preclinical and clinical studies are uncertain.
• The company's ability to fund development activities and achieve development goals.
• Reliance on third parties, including clinical research organizations, manufacturers, suppliers, and collaborators, over which the company may not always have full control.
• General geopolitical and macroeconomic conditions, including as a result of tariffs and various global conflicts.
• The company's ability to protect its intellectual property.

Future Outlook

The company plans to advance aleniglipron into Phase 3 clinical development by mid-2026, following a Type B End-of-Phase 2 meeting with the FDA in the first half of 2026 to finalize the Phase 3 design. The Phase 3 program is currently designed with a 2.5 mg starting titration dose and the intent to evaluate multiple doses up to 240 mg. Further topline results from the ACCESS OLE, ACCESS II Extension, Body Composition, SWITCH, and T2DM studies are expected in 2026, along with Phase 1 study results for ACCG-2671 and the initiation of a Phase 1 study for ACCG-3535.

Management Comments

• "The topline results presented today show that aleniglipron is differentiated and delivered clinically meaningful, competitive and dose-dependent weight loss with a safety profile appropriate for chronic use in a disease that impacts millions of people." Raymond Stevens, Ph.D., CEO of Structure Therapeutics.
• "For the higher doses, the observed weight loss data at 36 weeks with no weight loss plateau is potentially best-in-class for oral small molecule GLP1s." Raymond Stevens, Ph.D., CEO of Structure Therapeutics.
• "These findings provide comprehensive information to move into Phase 3 development and reinforce aleniglipron’s potential to become a backbone oral small molecule therapy for obesity—one that is accessible, scalable, and combinable." Raymond Stevens, Ph.D., CEO of Structure Therapeutics.
• "The weight-lowering data from these ACCESS studies, without any evidence of a plateau by Week 36, are very encouraging—particularly weight loss of up to 15.3% in ACCESS II that hopefully will be confirmed in larger, longer-term studies." Julio Rosenstock, MD, Chair of the ACCESS program Steering Committee.
• "As once-daily oral, non-peptide, small molecule GLP-1 RAs such as aleniglipron become available, they have the potential to transform obesity treatment and broaden access, which could have a profound impact on patients globally." Julio Rosenstock, MD.
• "A once-daily oral therapy like aleniglipron has the potential to expand treatment options for people living with obesity." Joe Nadglowski, Obesity Action Coalition President and CEO.

Industry Context

The announcement highlights the significant global unmet need in obesity treatment, with current injectable peptide GLP-1s reaching less than 5% of the addressable market. Oral small molecules like aleniglipron are positioned as a potential solution to address this gap due to their inherent advantages in accessibility, scalability, and combinability. The company aims to establish aleniglipron as a foundational oral small molecule therapy for obesity, capable of transforming treatment access and impact for millions of patients worldwide.

Comparison to Industry Standards

• The observed weight loss data at 36 weeks, with no weight loss plateau and up to 15.3% placebo-adjusted mean weight loss, is considered "potentially best-in-class for oral small molecule GLP1s."
• Aleniglipron, as an oral small molecule, is presented as a solution to the scalability limitations and higher costs associated with traditional biologic and peptide therapies (e.g., injectable GLP-1s like tirzepatide or oral semaglutide).
• Its once-daily pill administration, potential for fixed-dose combinations, simple manufacturing, and room temperature storage offer distinct advantages over injectables (which require once-weekly injections and refrigeration) and other oral peptides (which often require pre-dose fasting and have lower feasibility for fixed-dose combinations).
• The company believes aleniglipron is differentiated and delivered clinically meaningful, competitive, and dose-dependent weight loss, aiming to surpass the limitations of existing therapies.

Stakeholder Impact

• Shareholders: Highly positive impact due to strong clinical data for a lead drug candidate, significantly de-risking the development process and increasing potential market value and future revenue streams.
• Patients (Obesity/Overweight): Potential for a new, highly effective, accessible, and convenient oral treatment option, particularly beneficial for those who prefer oral medication or face barriers to injectable therapies.
• Healthcare Providers: Provides a promising new therapeutic tool for managing obesity and related comorbidities, potentially broadening treatment access and improving patient outcomes.
• Competitors: May face increased competitive pressure from a potentially best-in-class oral GLP-1, especially given its scalability and tolerability profile.

Next Steps

• Request a Type B End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in the first half of 2026 to finalize the Phase 3 design.
• Initiate the Phase 3 program by mid-2026.
• Report topline results for the ACCESS OLE, ACCESS II Extension, and Body Composition studies in the first half of 2026.
• Report topline results from the maintenance switching study (SWITCH study) in the second half of 2026.
• Report topline results from the Phase 2 randomized placebo-controlled study in patients with obesity or overweight and type 2 diabetes mellitus (T2DM study) in the second half of 2026.
• Receive Phase 1 study results for ACCG-2671, a dual amylin calcitonin receptor agonist (DACRA), in the second half of 2026.
• Initiate a Phase 1 study for its second DACRA development candidate, ACCG-3535, in the second half of 2026.

Key Dates

Recommendation

The positive topline data for aleniglipron, particularly the significant weight loss observed (up to 15.3% placebo-adjusted) and the favorable safety and tolerability profile, positions Structure Therapeutics as a strong contender in the rapidly growing obesity market. The successful dose optimization strategy to improve tolerability and the clear path to Phase 3 development de-risks the asset considerably. The potential for aleniglipron to be a "best-in-class" oral GLP-1, coupled with its scalability and accessibility advantages over injectables, suggests substantial commercial potential. The company's robust cash position and multiple upcoming catalysts further support a strong buy recommendation for long-term investors.

Keywords

obesity, GLP-1 receptor agonist, aleniglipron, weight loss, clinical trial, Phase 2b, Phase 3, biopharmaceutical, metabolic disease, oral small molecule, Structure Therapeutics, GPCR